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RNA activation (RNAa) is a newly discovered mechanism in which non-coding RNAs like small double-stranded 
RNAs (dsRNAs) or micro RNAs (miRNAs) induce sequence-specific gene activation by targeting promoter. 
Although its underlying mechanism remains unclear, we and others have demonstrated that Ago protein, RNA 
polymerase II (RNA Pol II) and heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNPA2/B1) are required for 
RNAa. In addition, RNAa is conserved in mammalian cells. Increasing evidences indicated that dsRNAs or 
miRNAs can induce tumor suppressing genes expression and hold great capacity to inhibit bladder cancer cells. 
RNAa provides a novel method for gene manipulation and offers an exciting potential for therapeutic modality 
against bladder cancers. In this review, we will focus on the research advances in exploiting the mechanism of 
RNAa and its applications in bladder cancer therapeutics. 
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Introduction 
Bladder cancer represents one of the most common 
malignancy worldwide and has a high mortality [1]. 
Tumorigenesis is often caused by long-term accumulation of 
genes’ mutation including overexpression of oncogenes or 
silencing of tumor suppressing genes [2]. In the past decades, 
RNA interference (RNAi) technique has emerged as a 
hallmark in basic and clinic research of cancers, and exhibits 
great potential for anti-cancer therapeutics [3]. Thus, 
knockdown of specific oncogenes undoubtedly contributes to 
cancer management. 
However, some cancers may mainly originate from low 
expression of the tumor suppressors and can’t be addressed 
by RNAi [4]. In this regard, up-regulation of their expression 
would likewise provide a promising approach for 
gene-specific therapeutics. Recently, small double-stranded 
RNAs (dsRNAs) or micro RNAs (miRNAs) have also been 
known to induce gene expression by targeting promoter or 
antisense of transcripts [5-8]. This positive gene regulation 
phenomenon was referred to as RNA activation (RNAa) and 
the dsRNAs were termed as small activating RNAs 
(saRNAs). In this review, we focus on the observations up to 
now on saRNAs mediated tumor suppressing genes 
activation in bladder cancer, especially its applications in 
cancer therapy and gene functional research in bladder 
cancer. 
Mechanism of RNAa 
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Although the definite mechanism of RNAa has not been 
characterized, many studies have identified some vital 
aspects of RNAa and made a great progress in exploring the 
mechanism [9-12]. Based on the current knowledge, the 
mechanism of RNAa involves transcriptional and epigenetic 
changes. The small non-coding RNAs (such as exogenously 
introduced dsRNAs or endogenously transcribed miRNAs) 
are loaded onto an Argonaute (Ago) protein which is 
commonly located in the cytoplasm. The loaded RNAs are 
processed to form an active Ago-RNA complex with the 
guide strand and meanwhile remove the other strand. Then 
the complex enters the nucleus via active or passive 
transport. Afterwards, the Ago-RNA complex is guided by 
the guide strand and enriches at the complementary target 
regions in either promoter DNA or non-coding RNA which 
is tethered to the promoter DNA. Subsequently, target gene 
is transcriptionally activated through modification of 
chromatin structure and epigenetic state. There are two 
different potential models for this process. One is that the 
Ago protein is guided to its DNA target and recruits histone 
modifying enzymes, making chromatin remodeled and 
activating transcription. The other is that the complementary 
RNA directly interacts with cognate promoter transcripts and 
attracts histone modifying enzymes to activate transcriptional 
expression. 
We and others have shown that Ago protein, RNA 
polymerase II (RNA Pol II) and heterogeneous nuclear 
ribonucleoprotein A2/B1 (hnRNPA2/B1) are required for 
RNAa [5, 12]. Furthermore, the process of RNAa is associated 
with epigenetic modifications around the target sequences of 
promoter, which including the loss of suppressive epigenetic 
enzymes such as histone H3 Lys9 di-methylation 
(H3K9me2), histone H3 Lys9 tri-methylation (H3K9me3), 
H3K27 tri-methylation (H3K27me3) and histone H3K4 
acetylation (H3K4ac), H3K9 acetylation (H3K9ac) or gain of 
active epigenetic enzymes such as H3K4 di-methylation 
(H3K4me2) and H3K4 tri-methylation (H3K4me3) [5, 12-14]. 
This means that the histone methylation and de-acetylation 
statuses have close relationship with gene activation [14]. It is 
disappointed that we still can’t realize this epigenetic 
modifications are the causes or consequences of elevated 
gene expression by RNAa. On the other hand, Li et al. have 
reported DNA methylation does not appear to affect RNAa 
[5]. But previous studies indicated promoter DNA sequences 
with hypermethylation are poor targets for saRNAs [15-17], 
and the CpG islands is deliberately avoided when designing 
saRNAs [5, 18]. 
Interestingly, RNAa may also be achieved by inducing the 
degradation of natural antisense transcripts [19, 20]. There are 
two preconditions needed for this gene modulation. First of 
all, the target gene must coexist with the expressed natural 
antisense transcript and widespread expression of natural 
antisense transcript would assist the specific interaction. 
Secondly, the natural antisense transcript must have an 
inhibitory effect on the cognate sense DNA of target gene [21, 
22]. Therefore, small RNA down-regulate the antisense 
transcriptional RNA and consequently leads to activation of 
the sense transcript. 
Features of RNAa 
At first, the synthetic dsRNAs fully complementary to 
specific gene promoter was identified to have the capacity to 
up-regulate target gene expression [5]. Soon after, some other 
types non-coding RNA, such as anti-gene RNAs (agRNAs) 
[14], piwi-interacting RNA (piRNAs) [23], micro RNAs 
(miRNAs) [6] and long non-coding RNAs (lncRNAs) [24], 
have been reported to mediate potent enhancement of target 
genes.  
In the initial studies, RNAa required saRNAs target genes’ 
promoters which locate about hundreds of nucleotides (nt) 
upstream relative to the transcriptional start site (TSS). 
Identical to standard small interfering RNAs (siRNAs), 
saRNAs have a length of 19 nt and a dTdT overhangs on the 
3’ terminal [5]. However, other RNAs like piRNAs and 
miRNAs with a different length and a different target region 
of gene DNA also possess the ability to activate gene 
expression [6, 10, 23, 24]. 
The kinetics of RNAa is distinct from traditional RNAi. It 
is now believed that RNAi can be triggered in several hours 
and lasts for only 5 - 7 days [25]. But RNAa does not emerge 
until 24 - 48 hours later following transfection and maintains 
effective for almost 2 weeks long [26]. Portnoy et al. proposed 
that RNAa acquires small RNAs get access to the nucleus as 
a nuclear process about gene transcription and change in 
chromatin structure [27]. This may contribute to the delayed 
RNAa activity and long-lasting effects. 
RNAa was initially observed in human cells [5, 14]. Then a 
small hairpin RNA (shRNA) was demonstrated to present 
RNAa by lentiviral-mediated overexpression in mouse cells 
both in vivo and in vitro [13]. Besides, several studies have 
indicated that RNAa was discovered in other mammalian 
species, such as rat and nonhuman primates [18]. This is due 
to nonhuman primates share almost the same genome 
sequences with human. Most saRNAs designed to target 
promoters of human genes can up-regulate the cognate genes 
expression in nonhuman primates as well. This suggests that 
RNAa phenomenon is well-conserved in mammalian cells 
[18]. In contrast, the promoter sequences of human diverge 
significantly from rodents. Hereby, validating saRNAs in 
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nonhuman primates disease models other than rodents may 
hold clinic applicability for RNAa-based therapeutics. 
Application of dsRNAs in bladder cancer research 
The experimental application of RNAa triggered by 
synthetic dsRNAs has been exploited [5, 28, 29]. Moreover, the 
effectiveness and safety of RNAa for gene manipulation is 
promising, since no non-specific genes expression alternation 
[5]. Bladder cancer can be handled via re-activating tumor 
suppressor or pro-apoptotic genes mediated by RNAa. 
p21Waf1/CIP1 (p21), a potent cyclin-dependent kinase 
(CDK) inhibitor, plays an essential role in blocking cell 
transition from phase G1 to S and promotion of apoptosis [30]. 
Up-regulation of p21 by RNAa would surely prevent cancers 
[31-35]. We have reported that a dsRNA (dsP21-322) targeting 
the promoter of p21 at -322 relative to TSS has the capacity 
to induce p21 expression in human bladder cancer cell lines 
and significantly inhibits bladder cancer cells proliferation 
and clonogenicity, causes acceleration of cell apoptosis and 
accumulation in G0/G1 phase in vitro [28]. Kang et al. showed 
that duplex dsP21-322 and the chemically modified variant 
stimulate p21 expression and induce cell-cycle arrest, 
apoptosis in bladder cancer. In addition, intravesical delivery 
of dsP21-322 derivative into mouse bladder facilitates p21 
expression in vivo and extends survival of mice in 
established orthotopic bladder cancer models [36]. Yang and 
colleagues also confirmed that dsP21-322 decreases 
proliferation and viability of bladder cancer cells through 
RNAa in a time- and dose-dependent manner [37]. 
It is known that invasion and metastasis are considered as 
the hallmarks of tumor progression. The 
epithelial-to-mesenchymal transition (EMT) process plays an 
important role in tumor invasion and metastasis [38]. Loss of 
epithelial cell marker such as E-cadherin characteristically 
would result in EMT [39]. Then tumor cells undergo 
alterations in morphology and motility [40]. However, RNAa 
has been demonstrated to restore E-cadherin expression and 
suppress migration and invasion of bladder cancer cells in 
vitro [41]. This phenomenon was also discovered in other 
cancer cells, such as breast cancer and prostate cancer [42, 43].  
miRNAs mediated RNAa in bladder cancer 
miRNAs are small non-coding endogenous RNAs with 
length of approximate 19-22 nt and have been proved to play 
crucial roles in carcinogenesis [44]. Place et al. have 
previously shown that miR-373 can readily induce 
E-cadherin expression in prostate cancer cell line PC3 by 
targeting promoter [6]. We have also reported that 
miR-370-5p, miR-1180-5p and miR-1236-3p positively 
regulate p21 expression in bladder cancer cell lines by 
p21-promoter binding and promote bladder cancer cells 
senescence, G0/G1 arrest and apoptosis. In addition, 
overexpression of the 3 miRNAs potently inhibits bladder 
cancer cells proliferation, colony formation and represses 
invasion and migration [45]. 
So far, studies about application of miRNAs mediated 
RNAa in human bladder cancer are scarce. However, Huang 
and colleagues identified miR-744 and miR-1186 
significantly enable Cyclin B1 expression by targeting 
different sites of gene promoter in mouse cancer cell lines. 
Long-term overexpression of the both miRNAs cause 
prolonged activation of Cyclin B1 and thus lead to 
chromosomal instability and stunted tumor growth [46]. These 
outcomes supports the possibility that low expression 
miRNAs of bladder cancer can be manipulated via RNAa 
and it facilitates to eradicate tumors. 
It is currently believed that sequences complementarity 
between RNA and its targeted promoter is necessary for 
RNAa. Previous experiments have indicated that different 
dsRNAs or miRNAs targeting different regions of the 
promoters of specific genes still exhibit activating activities 
[34, 45, 47]. We have shown that a mismatch between miRNAs 
and p21 promoter is tolerable to activate p21 expression [45]. 
This promoted us to speculate that whether candidate 
dsRNAs fully complementary to validated miRNAs targeted 
sites in p21 promoter still have the capacity to induce p21 
expression. At present, we synthesized a candidate 
dsP21-397 with perfect complementarity to miR-1180-5p 
target site of p21 promoter also can induce p21 up-regulation 
and inhibit Cyclin D1-CDK4/6 expression. Moreover, 
short-term transfection of dsP21-397 significantly suppresses 
bladder cancer cells, including induces cell cycle arrest and 
inhibits proliferation. Notably, dsP21-397 inhibits bladder 
cancer cells largely depended on modulating p21. 
Perspectives 
It is expected that RNAa may participate in a great range 
of applications in the future. In a particular signal pathway, 
the up-stream and down-stream tumor suppressing genes can 
be activated simultaneously, then yield a cascade effect of 
the target gene. Besides, the tumor suppressor and oncogene 
can be regulated by RNAa and RNAi at the same time, 
respectively. It is worth to note that combined transfection of 
saRNA and miRNA which target the same gene promoter 
site fails to further induce gene expression than single 
transfection of saRNA or miRNA with similar concentration 
[6]. However, it remains unclear that whether co-transfection 
of two distinct saRNAs or miRNAs targeting different sites 
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of the same gene promoter can result in more expression than 
single transfection. 
The RNAa phenomenon is a recently discovered 
mechanism for positive gene regulation. Selecting the 
optimal genomic regions for non-coding RNAs targeting is a 
critical element for RNAa. It is proposed that the effective 
target sites for RNAa are within the promoter sequences and 
near to the TSS [5, 48]. In last study, 4 human miRNAs 
(miR-103b, miR-370-5p, miR-1180-5p and miR-1236-3p) 
targeted p21 promoter were identified through the miRanda 
program. Of the 4 miRNAs, miR-103b failed to induce p21 
expression, it may be resulted from its long distance from the 
TSS and some other factors, such as thermodynamic 
properties, chromatin/DNA accessibility [27]. In addition, the 
non-coding RNAs with relative higher alignment score and 
lower minimum free energy are suitable candidates for 
RNAa [49]. 
Although a great number of studies have been conducted 
to test the design principles of small RNAs used for gene 
activation, until now the design remains a hit-or-miss process 
[18]. Therefore, more researches are needed to clarify the 
saRNAs design rules and enhance the possibility of gene 
activation. Off-target effect is another problem which is 
urgent to be settled. In order to avoid sequence-specific 
off-target effect, the designed candidate saRNAs should lack 
significant homology to all known human sequences. 
Additionally, transport of the biomolecules (non-coding 
RNAs) into cells, tissues and organs directly decides the 
success ratio of RNAa. So the key criterion is elevating 
delivery efficiency including improving RNAs structure, 
optimizing transfecting condition and transfection reagent. 
Conclusion 
In summary, RNAa emerges as a cancer treatment 
alternative by re-activating tumor suppressor even its 
underlying mechanism remains elusive. It provides a new 
platform for functional genes study and offers attractive 
potential for clinical translation. Contrary to traditional 
RNAi, saRNAs and miRNAs potently inhibit bladder cancer 
by stimulating tumor suppressing genes’ expression. Along 
with the advancement of research, RNAa-based therapeutics 
will make a better prognosis for cancer patients.  
Acknowledgments 
This work was supported by the National Natural Science 
Foundation of China (grant number 81372759, China). We 
apologize to the authors whose important work we were not 
able to cite in this review. 
Conflict of interests 
All authors declare no conflict of interests. 
References 
1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA 
Cancer J Clin 2014;64:9-29. 
2. Cancer Genome Atlas Research N. Comprehensive molecular 
characterization of urothelial bladder carcinoma. Nature 
2014;507:315-322. 
3. Wang Z, Rao DD, Senzer N, Nemunaitis J. RNA interference and 
cancer therapy. Pharm Res 2011;28:2983-2995. 
4. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. 
Nat Rev Cancer 2005;5:713-725. 
5. Li LC, Okino ST, Zhao H, Pookot D, Place RF, Urakami S, et al. 
Small dsRNAs induce transcriptional activation in human cells. 
Proc Natl Acad Sci U S A 2006;103:17337-17342. 
6. Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R. 
MicroRNA-373 induces expression of genes with complementary 
promoter sequences. Proc Natl Acad Sci USA 
2008;105:1608-1613. 
7. Morris KV, Santoso S, Turner AM, Pastori C, Hawkins PG. 
Bidirectional transcription directs both transcriptional gene 
activation and suppression in human cells. PLoS Genet 
2008;4:e1000258. 
8. Schwartz JC, Younger ST, Nguyen NB, Hardy DB, Monia BP, 
Corey DR, et al. Antisense transcripts are targets for activating 
small RNAs. Nat Struct Mol Biol 2008;15:842-848. 
9. Li LC. Chromatin remodeling by the small RNA machinery in 
mammalian cells. Epigenetics 2014;9:45-52. 
10. Rossi JJ. Transcriptional activation by small RNA duplexes. Nat 
Chem Biol 2007;3:136-137. 
11. Jiao AL, Slack FJ. RNA-mediated gene activation. Epigenetics 
2014;9:27-36. 
12. Hu J, Chen Z, Xia D, Wu J, Xu H, Ye ZQ. Promoter-associated 
small double-stranded RNA interacts with heterogeneous nuclear 
ribonucleoprotein A2/B1 to induce transcriptional activation. 
Biochem J 2012;447:407-416. 
13. Turunen MP, Lehtola T, Heinonen SE, Assefa GS, Korpisalo P, 
Girnary R, et al. Efficient regulation of VEGF expression by 
promoter-targeted lentiviral shRNAs based on epigenetic 
mechanism: a novel example of epigenetherapy. Circ Res 
2009;105:604-609. 
14. Janowski BA, Younger ST, Hardy DB, Ram R, Huffman KE, 
Corey DR. Activating gene expression in mammalian cells with 
promoter-targeted duplex RNAs. Nat Chem Biol 2007;3:166-173. 
15. Morris KV, Chan SW, Jacobsen SE, Looney DJ. Small interfering 
RNA-induced transcriptional gene silencing in human cells. 
Science 2004;305:1289-1292. 
16. Ting AH, Schuebel KE, Herman JG, Baylin SB. Short 
double-stranded RNA induces transcriptional gene silencing in 
human cancer cells in the absence of DNA methylation. Nat Genet 
2005;37:906-910. 
17. Castanotto D, Tommasi S, Li M, Li H, Yanow S, Pfeifer GP, et al. 
RNA & DISEASE 2015; 2: e595. doi: 10.14800/rd.595; © 2015 by Chenghe Wang, et al. 
http://www.smartscitech.com/index.php/rd 
 
Page 5 of 5 
 
Short hairpin RNA-directed cytosine (CpG) methylation of the 
RASSF1A gene promoter in HeLa cells. Mol Ther 
2005;12:179-183. 
18. Huang V, Qin Y, Wang J, Wang XL, Place RF, Lin GT, et al. 
RNAa Is Conserved in Mammalian Cells. PloS one 2010;5. 
19. Morris KV. Long antisense non-coding RNAs function to direct 
epigenetic complexes that regulate transcription in human cells. 
Epigenetics 2009;4:296-301. 
20. Wahlestedt C. Natural antisense and noncoding RNA transcripts 
as potential drug targets. Drug Discov Today 2006;11:503-508. 
21. Modarresi F, Faghihi MA, Lopez-Toledano MA, Fatemi RP, 
Magistri M, Brothers SP, et al. Inhibition of natural antisense 
transcripts in vivo results in gene-specific transcriptional 
upregulation. Nat Biotechnol 2012;30:453-459. 
22. Johnsson P, Ackley A, Vidarsdottir L, Lui WO, Corcoran M, 
Grander D, et al. A pseudogene long-noncoding-RNA network 
regulates PTEN transcription and translation in human cells. Nat 
Struct Mol Biol 2013;20:440-446. 
23. Yin H, Lin H. An epigenetic activation role of Piwi and a 
Piwi-associated piRNA in Drosophila melanogaster. Nature 
2007;450:304-308. 
24. Wang KC, Yang YW, Liu B, Sanyal A, Corces-Zimmerman R, 
Chen Y, et al. A long noncoding RNA maintains active chromatin 
to coordinate homeotic gene expression. Nature 
2011;472:120-124. 
25. Dykxhoorn DM, Novina CD, Sharp PA. Killing the messenger: 
Short RNAs that silence gene expression. Nat Rev Mol Cell Bio 
2003;4:457-467. 
26. Place RF, Noonan EJ, Foldes-Papp Z, Li LC. Defining features 
and exploring chemical modifications to manipulate RNAa 
activity. Curr Pharm Biotechnol 2010;11:518-526. 
27. Portnoy V, Huang V, Place RF, Li LC. Small RNA and 
transcriptional upregulation. Wiley Interdiscip Rev RNA 
2011;2:748-760. 
28. Chen Z, Place RF, Jia ZJ, Pookot D, Dahiya R, Li LC. Antitumor 
effect of dsRNA-induced p21(WAF1/CIP1) gene activation in 
human bladder cancer cells. Mol Cancer Ther 2008;7:698-703. 
29. Whitson JM, Noonan EJ, Pookot D, Place RF, Dahiya R. Double 
stranded-RNA-mediated activation of P21 gene induced apoptosis 
and cell cycle arrest in renal cell carcinoma. Int J Cancer 
2009;125:446-452. 
30. Wang H, Zhu LJ, Yang YC, Wang ZX, Wang R. MiR-224 
promotes the chemoresistance of human lung adenocarcinoma 
cells to cisplatin via regulating G(1)/S transition and apoptosis by 
targeting p21(WAF1/CIP1). Br J Cancer 2014;111:339-354. 
31. Zhang Z, Wang Z, Liu X, Wang J, Li F, Li C, et al. Up-regulation 
of p21WAF1/CIP1 by small activating RNA inhibits the in vitro 
and in vivo growth of pancreatic cancer cells. Tumori 
2012;98:804-811. 
32. Kosaka M, Kang MR, Yang G, Li LC. Targeted p21WAF1/CIP1 
activation by RNAa inhibits hepatocellular carcinoma cells. 
Nucleic Acid Ther 2012;22:335-343. 
33. Wei J, Zhao J, Long M, Han Y, Wang X, Lin F, et al. 
p21WAF1/CIP1 gene transcriptional activation exerts cell growth 
inhibition and enhances chemosensitivity to cisplatin in lung 
carcinoma cell. BMC cancer 2010;10:632. 
34. Place RF, Wang J, Noonan EJ, Meyers R, Manoharan M, Charisse 
K, et al. Formulation of Small Activating RNA Into Lipidoid 
Nanoparticles Inhibits Xenograft Prostate Tumor Growth by 
Inducing p21 Expression. Mol Ther Nucleic Acids 2012;1:e15. 
35. Dong Z, Dang Y, Chen Y. Small double-stranded RNA mediates 
the anti-cancer effects of p21WAF1/ClP1 transcriptional 
activation in a human glioma cell line. Yonsei Med J 
2014;55:324-330. 
36. Kang MR, Yang G, Place RF, Charisse K, Epstein-Barash H, 
Manoharan M, et al. Intravesical Delivery of Small Activating 
RNA Formulated into Lipid Nanoparticles Inhibits Orthotopic 
Bladder Tumor Growth. Cancer Res 2012;72:5069-5079. 
37. Yang K, Zheng XY, Qin J, Wang YB, Bai Y, Mao QQ, et al. 
Up-regulation of p21WAF1/Cip1 by saRNA induces G1-phase 
arrest and apoptosis in T24 human bladder cancer cells. Cancer 
Lett 2008;265:206-214. 
38. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et 
al. The epithelial-mesenchymal transition generates cells with 
properties of stem cells. Cell 2008;133:704-715. 
39. Imao T, Koshida K, Endo Y, Uchibayashi T, Sasaki T, Namiki M. 
Dominant role of E-cadherin in the progression of bladder cancer. 
J Urol 1999;161:692-698. 
40. Thiery JP. Epithelial-mesenchymal transitions in tumour 
progression. Nat Rev Cancer 2002;2:442-454. 
41. Mao Q, Li Y, Zheng X, Yang K, Shen H, Qin J, et al. 
Up-regulation of E-cadherin by small activating RNA inhibits cell 
invasion and migration in 5637 human bladder cancer cells. 
Biochem Biophys Res Commun 2008;375:566-570. 
42. Junxia W, Ping G, Yuan H, Lijun Z, Jihong R, Fang L, et al. 
Double strand RNA-guided endogeneous E-cadherin up-regulation 
induces the apoptosis and inhibits proliferation of breast 
carcinoma cells in vitro and in vivo. Cancer Sci 
2010;101:1790-1796. 
43. Mao Q, Zheng X, Yang K, Qin J, Bai Y, Jia X, et al. Suppression 
of migration and invasion of PC3 prostate cancer cell line via 
activating E-cadherin expression by small activating RNA. Cancer 
Invest 2010;28:1013-1018. 
44. Fendler A, Stephan C, Yousef GM, Jung K. MicroRNAs as 
regulators of signal transduction in urological tumors. Clin Chem 
2011;57:954-968. 
45. Wang C, Chen Z, Ge Q, Hu J, Li F, Hu J, et al. Up-regulation of 
p21(WAF1/CIP1) by miRNAs and its implications in bladder 
cancer cells. FEBS Lett 2014;588:4654-4664. 
46. Huang V, Place RF, Portnoy V, Wang J, Qi Z, Jia Z, et al. 
Upregulation of Cyclin B1 by miRNA and its implications in 
cancer. Nucleic Acids Res 2012;40:1695-1707. 
47. Wang J, Huang V, Ye L, Barcena A, Lin G, Lue TF, et al. 
Identification of Small Activating RNAs that Enhance 
Endogenous OCT4 Expression in Human Mesenchymal Stem 
Cells. Stem Cells Dev 2015;24:345-353. 
48. Garber K. Genetics. Small RNAs reveal an activating side. 
Science 2006;314:741-742. 
49. Younger ST, Pertsemlidis A, Corey DR. Predicting potential 
miRNA target sites within gene promoters. Bioorg Med Chem 
Lett 2009;19:3791-3794. 
